 DUBLIN, Ohio--BUSINESS WIRE--Navidea Biopharmaceuticals, Inc. NYSE American: NAVB Navidea or the Company, a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the closing of its rights offering and the final results thereof. Navidea received aggregate gross cash proceeds of approximately 6.2 million in the rights offering. If exercised, additional gross proceeds of up to 11.6 million may be received through the exercise of 